Halozyme Therapeutics (HALO) Tops Q4 EPS by 3c; Guides FY15 Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Halozyme Therapeutics (HALO) PT Raised to $26 at BMO Capital
March 3, 2015 7:23 AM ESTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on Halozyme Therapeutics (NASDAQ: HALO) to $26.00 (from $24.00) following Q4 results.
Birchenough commented, "We are reiterating our Outperform rating on the shares of HALO following review of 4Q14 progress.... More
Halozyme Therapeutics (HALO) Raised to $19 at Piper Jaffray
March 3, 2015 7:17 AM ESTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $17.00) following Q4 results.. The firm said proprietary program visibility should increase in 2015.
Duncan commented, "On Monday AMC, Halozyme reported 4Q/FY14 results, reiterating 2015... More
